
Boulder firm Array BioPharma posts $147M loss as cancer drug combo launches
Boulder pharmaceutical firm Array BioPharma, Inc. posted losses of more than $147.3 million for the full 2018 fiscal year, which ended June 30. That loss is up from $116.8 million...








